TB (Tuberculosis) Preventive Therapy for HIV Patients With Access to HAART (Highly Active Antiretroviral Therapy)

• Status: Completed
• Trial end date: 2010-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if implementing a policy of widespread INH (Isoniazid) prophylaxis therapy in HIV-infected patients with access to antiretroviral therapy reduces the incidence of active TB disease in the HIV clinic population.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Johns Hopkins University
• Collaborators: Bill and Melinda Gates Foundation; Communicable Disease Program, Brazil; Consortium to Respond Effectively to the AIDS/Tuberculosis Epidemic

Criteria

Inclusion Criteria:

• Attending 1 of 29 participating HIV clinics

• Confirmed HIV infection

• Age > 15 years

Exclusion Criteria:

• Current active TB disease

• TB infection within 2 years

• Hepatitis